Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Brittney Mott; Sanjay Thamake; Jamboor Vishwanatha; Harlan P. Jones

doi:10.1007/s11051-013-1646-x

Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Brittney Mott, Sanjay Thamake, Jamboor Vishwanatha, Harlan P. Jones

Microbiology, Immunology & Genetics

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Nanoparticle (NP) technologies are becoming commonplace in the development of vaccine delivery systems to protect against various diseases. The current study determined the efficacy of intranasal delivery of a 234 ± 87.5 nm poly lactic-co-glycolic acid nanoparticle vaccine construct in establishing protection against experimental respiratory pneumococcal infection. Nanoparticles encapsulating heat-killed Streptococcus pneumoniae (NP-HKSP) were retained in the lungs 11 days following nasal administration compared to empty NP. Immunization with NP-HKSP produced significant resistance against S. pneumoniae infection compared to administration of HKSP alone. Increased protection correlated with a significant increase in antigen-specific Th1-associated IFN-γ cytokine response by pulmonary lymphocytes. This study establishes the efficacy of NP-based technology as a non-invasive and targeted approach for nasal-pulmonary immunization against pulmonary infections.

Original language	English
Article number	1646
Journal	Journal of Nanoparticle Research
Volume	15
Issue number	5
DOIs	https://doi.org/10.1007/s11051-013-1646-x
State	Published - May 2013

Keywords

Immunity
Nanoparticle
Respiratory
Streptococcus pneumoniae
Vaccine

Access to Document

10.1007/s11051-013-1646-x

Cite this

@article{46d93b86695a46abbe78922669e924c0,

title = "Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae",

abstract = "Nanoparticle (NP) technologies are becoming commonplace in the development of vaccine delivery systems to protect against various diseases. The current study determined the efficacy of intranasal delivery of a 234 ± 87.5 nm poly lactic-co-glycolic acid nanoparticle vaccine construct in establishing protection against experimental respiratory pneumococcal infection. Nanoparticles encapsulating heat-killed Streptococcus pneumoniae (NP-HKSP) were retained in the lungs 11 days following nasal administration compared to empty NP. Immunization with NP-HKSP produced significant resistance against S. pneumoniae infection compared to administration of HKSP alone. Increased protection correlated with a significant increase in antigen-specific Th1-associated IFN-γ cytokine response by pulmonary lymphocytes. This study establishes the efficacy of NP-based technology as a non-invasive and targeted approach for nasal-pulmonary immunization against pulmonary infections.",

keywords = "Immunity, Nanoparticle, Respiratory, Streptococcus pneumoniae, Vaccine",

author = "Brittney Mott and Sanjay Thamake and Jamboor Vishwanatha and Jones, {Harlan P.}",

year = "2013",

month = may,

doi = "10.1007/s11051-013-1646-x",

language = "English",

volume = "15",

journal = "Journal of Nanoparticle Research",

issn = "1388-0764",

publisher = "Springer Netherlands",

number = "5",

}

TY - JOUR

T1 - Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

AU - Mott, Brittney

AU - Thamake, Sanjay

AU - Vishwanatha, Jamboor

AU - Jones, Harlan P.

PY - 2013/5

Y1 - 2013/5

N2 - Nanoparticle (NP) technologies are becoming commonplace in the development of vaccine delivery systems to protect against various diseases. The current study determined the efficacy of intranasal delivery of a 234 ± 87.5 nm poly lactic-co-glycolic acid nanoparticle vaccine construct in establishing protection against experimental respiratory pneumococcal infection. Nanoparticles encapsulating heat-killed Streptococcus pneumoniae (NP-HKSP) were retained in the lungs 11 days following nasal administration compared to empty NP. Immunization with NP-HKSP produced significant resistance against S. pneumoniae infection compared to administration of HKSP alone. Increased protection correlated with a significant increase in antigen-specific Th1-associated IFN-γ cytokine response by pulmonary lymphocytes. This study establishes the efficacy of NP-based technology as a non-invasive and targeted approach for nasal-pulmonary immunization against pulmonary infections.

AB - Nanoparticle (NP) technologies are becoming commonplace in the development of vaccine delivery systems to protect against various diseases. The current study determined the efficacy of intranasal delivery of a 234 ± 87.5 nm poly lactic-co-glycolic acid nanoparticle vaccine construct in establishing protection against experimental respiratory pneumococcal infection. Nanoparticles encapsulating heat-killed Streptococcus pneumoniae (NP-HKSP) were retained in the lungs 11 days following nasal administration compared to empty NP. Immunization with NP-HKSP produced significant resistance against S. pneumoniae infection compared to administration of HKSP alone. Increased protection correlated with a significant increase in antigen-specific Th1-associated IFN-γ cytokine response by pulmonary lymphocytes. This study establishes the efficacy of NP-based technology as a non-invasive and targeted approach for nasal-pulmonary immunization against pulmonary infections.

KW - Immunity

KW - Nanoparticle

KW - Respiratory

KW - Streptococcus pneumoniae

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84876189630&partnerID=8YFLogxK

U2 - 10.1007/s11051-013-1646-x

DO - 10.1007/s11051-013-1646-x

M3 - Article

AN - SCOPUS:84876189630

SN - 1388-0764

VL - 15

JO - Journal of Nanoparticle Research

JF - Journal of Nanoparticle Research

IS - 5

M1 - 1646

ER -

Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this